First-in-Human Phase I Study of PRS-050 (Angiocal), an Anticalin Targeting and Antagonizing VEGF-A, in Patients with Advanced Solid Tumors

BACKGROUND: To report the nonrandomized first-in-human phase I trial of PRS-050, a novel, rationally engineered Anticalin based on human tear lipocalin that targets and antagonizes vascular endothelial growth factor A (VEGF-A). METHODS: Patients with advanced solid tumors received PRS-050 at 0.1 mg/...

Descripción completa

Detalles Bibliográficos
Autores principales: Mross, Klaus, Richly, Heike, Fischer, Richard, Scharr, Dirk, Büchert, Martin, Stern, Angelika, Gille, Hendrik, Audoly, Laurent P., Scheulen, Max E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862718/
https://www.ncbi.nlm.nih.gov/pubmed/24349470
http://dx.doi.org/10.1371/journal.pone.0083232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862718/
https://www.ncbi.nlm.nih.gov/pubmed/24349470
http://dx.doi.org/10.1371/journal.pone.0083232

Ejemplares similares